Gilead Sciences, Inc. (GILD)
译 Gilead Sciences' COVID-19 Treatment Earns Conditional Approval in Europe Now, Gilead can market Veklury throughout the EU for the treatment of COVID-19 in patients 12 years of age and older with pneumonia serious enough to require supplemental oxygen in a hospital setting ... The EU based its conditional approval on results of a study that showed severely-affected COVID-19 patients treated with Veklury recovered after 11 days compared to 15 days among those treated with a placebo ... The European Medicines Agency hasn't issued a specific mortality benefit threshold, but a complete lack of one could quickly result in withdrawal of Veklury's conditional approval.
motley fool · 8 hours ago
译 Gilead's remdesivir OK'd in Europe for COVID-19 The European Commission has conditionally approved Gilead Sciences' (NASDAQ:GILD) Veklury (remdesivir) for the treatment of patients at least 12 years old with COVID-19 pneumonia requiring supplemental oxygen ... The nod is initially valid for one year but can be extended or converted into unconditional approval upon the submission and assessment of additional confirmatory data.
SeekingAlpha · 8 hours ago
译 Why Gilead Sciences Shares Rose 18.4% in the First Half What happened Shares of Gilead Sciences (NASDAQ:GILD) rose 18.4% the first half, according to data provided by S&P Global Market Intelligence, as hospitals began using its drug remdesivir to treat COVID-19 patients ... Early into the health crisis, Gilead began testing remdesivir as a possible treatment for the illness caused by the novel coronavirus ... Strong evidence of remdesivir's efficacy in treating the virus and FDA approval are essential for Gilead to maintain a leading role in the COVID-19 field and generate long-term revenue from remdesivir.
motley fool · 9 hours ago